Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously... see more

Recent & Breaking News (NDAQ:IOVA)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Iovance Biotherapeutics, Inc. (IOVA)

Accesswire January 5, 2024

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire January 5, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

Accesswire January 4, 2024

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Iovance Biotherapeutics, Inc. (IOVA)

Accesswire January 4, 2024

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire January 4, 2024

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Iovance Biotherapeutics, Inc. (IOVA)

Accesswire January 3, 2024

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire January 3, 2024

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire January 2, 2024

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire January 1, 2024

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire December 31, 2023

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire December 29, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

PR Newswire December 28, 2023

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire December 28, 2023

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire December 27, 2023

Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

GlobeNewswire December 27, 2023

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire December 22, 2023

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire November 17, 2023

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates

GlobeNewswire November 7, 2023

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023

GlobeNewswire October 31, 2023

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire October 31, 2023